Wedbush Analysts Reduce Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Wedbush lowered their FY2026 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst L. Chico now expects that the company will post earnings of $4.29 per share for the year, down from their prior forecast of $4.50. Wedbush currently has a “Neutral” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.27) per share.

APLS has been the subject of several other research reports. Raymond James increased their price target on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research report on Thursday, January 11th. Citigroup lowered their target price on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday. Robert W. Baird reiterated an “outperform” rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. UBS Group cut their price target on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $76.67.

Apellis Pharmaceuticals Trading Down 3.6 %

Shares of APLS stock opened at $42.30 on Thursday. The firm’s fifty day simple moving average is $54.30 and its 200 day simple moving average is $57.42. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $5.13 billion, a P/E ratio of -9.44 and a beta of 0.97.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. Apellis Pharmaceuticals’s revenue for the quarter was up 284.3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.56) earnings per share.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of APLS. Vanguard Group Inc. increased its holdings in Apellis Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock worth $572,003,000 after purchasing an additional 85,701 shares during the period. Jennison Associates LLC increased its holdings in Apellis Pharmaceuticals by 79.8% in the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after acquiring an additional 1,571,606 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after buying an additional 677,098 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after purchasing an additional 1,121,497 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its stake in shares of Apellis Pharmaceuticals by 126.6% in the third quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock worth $40,089,000 after buying an additional 588,875 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Adam J. Townsend sold 1,148 shares of Apellis Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $77,799.96. Following the completion of the sale, the insider now owns 92,453 shares of the company’s stock, valued at $6,265,539.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Apellis Pharmaceuticals news, insider Adam J. Townsend sold 1,148 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $77,799.96. Following the sale, the insider now owns 92,453 shares in the company, valued at approximately $6,265,539.81. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 1,431 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $96,978.87. Following the completion of the transaction, the chief financial officer now owns 93,338 shares in the company, valued at $6,325,516.26. The disclosure for this sale can be found here. Insiders have sold a total of 376,427 shares of company stock valued at $23,169,639 over the last ninety days. 7.50% of the stock is currently owned by corporate insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).